CA2373851A1 - Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules - Google Patents

Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules Download PDF

Info

Publication number
CA2373851A1
CA2373851A1 CA002373851A CA2373851A CA2373851A1 CA 2373851 A1 CA2373851 A1 CA 2373851A1 CA 002373851 A CA002373851 A CA 002373851A CA 2373851 A CA2373851 A CA 2373851A CA 2373851 A1 CA2373851 A1 CA 2373851A1
Authority
CA
Canada
Prior art keywords
conjugate according
nucleic acid
molecule
antibody
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002373851A
Other languages
English (en)
French (fr)
Inventor
Francois Hirsch
Antoine Durrbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2373851A1 publication Critical patent/CA2373851A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
CA002373851A 1999-05-10 2000-05-10 Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules Abandoned CA2373851A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR99/05943 1999-05-10
FR9905943A FR2793414B1 (fr) 1999-05-10 1999-05-10 Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules
PCT/FR2000/001259 WO2000067697A2 (fr) 1999-05-10 2000-05-10 Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules

Publications (1)

Publication Number Publication Date
CA2373851A1 true CA2373851A1 (fr) 2000-11-16

Family

ID=9545418

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002373851A Abandoned CA2373851A1 (fr) 1999-05-10 2000-05-10 Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules

Country Status (7)

Country Link
EP (1) EP1175498A2 (ja)
JP (1) JP2002543810A (ja)
AU (1) AU4415200A (ja)
CA (1) CA2373851A1 (ja)
FR (1) FR2793414B1 (ja)
IL (1) IL146399A0 (ja)
WO (1) WO2000067697A2 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1592412A1 (en) * 2003-01-31 2005-11-09 Novartis AG Down-regulation of target-gene with pei/single-stranded oligoribonucleotide complexes
JP4521519B2 (ja) * 2003-05-26 2010-08-11 学校法人慶應義塾 部分ヒストンテイル型イムノポーター
FR2958645B1 (fr) * 2010-04-09 2012-08-31 Commissariat Energie Atomique Hemi-anticorps a auto-assemblage
US10540907B2 (en) 2014-07-31 2020-01-21 Intelligent Technologies International, Inc. Biometric identification headpiece system for test taking
US10410535B2 (en) 2014-08-22 2019-09-10 Intelligent Technologies International, Inc. Secure testing device
CN106662746B (zh) 2014-08-22 2020-10-23 国际智能技术公司 安全考试设备、系统和方法
US10438106B2 (en) 2014-11-04 2019-10-08 Intellignet Technologies International, Inc. Smartcard
CN108530540B (zh) * 2018-03-30 2021-06-15 华南农业大学 抗亚精胺单克隆抗体杂交瘤细胞株4e4及其单克隆抗体和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
EP0366707A1 (en) * 1987-05-06 1990-05-09 OOSTERWIJK, Egbert Monoclonal antibodies to renal cell carcinoma
US5428132A (en) * 1987-10-11 1995-06-27 United States Of America Conjugate and method for integration of foreign DNA into cells
IL106760A (en) * 1992-08-25 1999-12-31 Miles Inc Nuclear Acid Protein Hybrid Structure for Transferring Nucleic Acid from External Source to Cell and Target Nucleus
US5574142A (en) * 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
IL112372A (en) * 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
DE69521331T2 (de) * 1994-11-01 2001-09-20 Winfried Wels Nukleinsäure-einbringungssystem
GB9614699D0 (en) * 1996-07-12 1996-09-04 John P Robarts Research Inst T Hybrid herpes virus-based vector for gene delivery and expression
DE19717904A1 (de) * 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
AU742255B2 (en) * 1997-06-11 2001-12-20 School Of Pharmacy, University Of London, The Pharmaceutical compositions containing antibody-enzyme conjugates in combination with prodrugs

Also Published As

Publication number Publication date
IL146399A0 (en) 2002-07-25
EP1175498A2 (fr) 2002-01-30
AU4415200A (en) 2000-11-21
WO2000067697A3 (fr) 2001-06-28
JP2002543810A (ja) 2002-12-24
FR2793414B1 (fr) 2003-05-23
FR2793414A1 (fr) 2000-11-17
WO2000067697A2 (fr) 2000-11-16

Similar Documents

Publication Publication Date Title
US20210346504A1 (en) Exosomes For Delivery Of Biotherapeutics
Elfinger et al. Characterization of lactoferrin as a targeting ligand for nonviral gene delivery to airway epithelial cells
Xu et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes
JP3222461B2 (ja) 新規タンパク質―ポリカチオン結合体
US20070219118A1 (en) Therapeutic methods for nucleic acid delivery vehicles
Narang et al. Targeted delivery of small and macromolecular drugs
JP2002514892A (ja) 遺伝子治療における合成ウイルス様粒子の使用
KR20070061770A (ko) siRNA의 세포내 전달을 위한 siRNA와 친수성 고분자 간의접합체 및 그의 제조방법
JP2002502243A (ja) トランスフェクション活性を有するインテグリン−ターゲッティングベクター
Bäumer et al. Immunoprotein-mediated siRNA delivery
CN111989138A (zh) 人源化抗前列腺特异性膜抗原(psma)抗体药物缀合物
CA2373851A1 (fr) Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules
CA2101332C (en) Antibody polycation conjugates
May et al. Assessment of cell type specific gene transfer of polyoma virus like particles presenting a tumor specific antibody Fv fragment
US20240158814A1 (en) Dendritic peptide conjugated polymers for efficient intracellular delivery of nucleic acids to immune cells
Germershaus et al. HER2 targeted polyplexes: the effect of polyplex composition and conjugation chemistry on in vitro and in vivo characteristics
JP2023528293A (ja) 単一ドメイン抗体及びがん治療におけるその使用
González et al. Pegylation: An overview and recent advances reported in the patent literature
EP0934342B1 (fr) Composition contenant du chitosan
CN112876566A (zh) 一种cd3特异性慢病毒的构建及其应用
EP4238581A1 (en) Targeted delivery of oligonucleotides into eukaryotic cells using hybrid maltose/cyclodextrin polyplexes
Gao et al. Polymeric Gene Delivery Carriers for Pulmonary Diseases
Sadowski et al. Ligand-Mediated Modulation of the Type III Tyrosine-Kinase Receptor c-kit is a possible specific Entrance Mechanism for Immunotoxins in c-kit+ Leukemia
FR2754823A1 (fr) Nouveaux derives du chitosan, compositions comportant du chitosan ou ses derives et application de ces compositions sur le transfert d'acide nucleique dans une cellule hote

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued